Table 3.
Effect of thymol in different experimental models of metabolic disorders and nephrotoxicity.
Dose | Model | Target/End points |
Reference | |
---|---|---|---|---|
Increase | Decrease | |||
Diabetes Mellitus | ||||
40 mg/kg | High fat diet induced C57BL/6J mice | Adiponectin, LCAT, LPL, HDL-C, CPT, ME, PAP | Body weight, HOMA-IR, HbA1c, insulin, glucose, leptin, HMG-CoA reductase, plasma and hepatic lipid profile, fatty acid β-oxidation, activities of G6PD and FAS | Saravanan and Pari, 2015 |
40 mg/kg | High fat diet induced C57BL/6J mice | Serum protein,, SOD, catalase, GPx, GRx, GST, GSH, vitamin-C, vitamin-E in erythrocyte and kidney | Blood glucose, insulin, BUN, creatinine, TBARS, LOOH, erythrocytes and kidney, total cholesterol, TGs, FFAs, PLs in kidney,, gene expressions of SREBP-1c, TGF-β1, VEGF, lipid accumulation | Saravanan and Pari, 2016 |
0.5–2.0 mg/ml | AAPH induced diabetic erythrocytes | Free radical scavenging | Lipid peroxidation, RBC hemolysis | Aman et al., 2013 |
Obesity | ||||
30 mg/kg | HFD-induced murine model | HDL-C levels, SOD and catalase in serum | Body weight, food intake, serum and hepatic function parameters and lipid profile | Haque et al., 2014 |
20 μM | 3T3-L1 white adipocytes | Expressions of signaling molecules of glucose homeostasis and lipid metabolism | Cytotoxicity, LPL expression, TG accumulation | Choi et al., 2016 |
Nephrotoxicity | ||||
20 mg/kg | Cisplatin induced male adult Swiss albino rats | Antioxidants in kidney | Decrease creatinine and BUN, TNF-α, caspase-3 and MDA | El-Sayed et al., 2014 |
200–500 μM | MDCK cells | Ca2+, apoptosis, ROS | Cell viability | Chang et al., 2014 |
50 and 150 mg/kg | Cisplatin induced Swiss albino mice | Uptake of 99mTc-DMSA (dimer captosuccinic acid) | Tubular necrosis, degeneration, epithelial vacuolization, swelling | Hosseinimehr et al., 2015 |